Bioanalytical Services
 |
PharmaNet offers bioanalytical laboratory services through its subsidiaries: Anapharm, Anapharm Europe, Keystone Analytical and Taylor Technology.
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
Together, they offer over 1000 bioanalytical validated methods for one or more analytes from human or animal matrices.
Our laboratories can develop and validate custom (or project-specific) ELISAs or ligand-binding assays and can also develop and validate cell-based assays.
We are also actively working on developing proprietary methods that are not currently included in this list.
You may also view our list of biomarkers below.
List of BioMarkers
(Click here)
Contact us for more details.
(In alphabetically order)
 |
 |
 |
 |
 |
| Acamprosate | Central Nervous System Agents | LCMSMS | 0.5-200 ng/mL | Human EDTA Plasma |
| Aceclofenac | Pain | LC/MS/MS | 15-15000 ng/mL | Human EDTA Plasma |
| Acetaminophen | Pain | LC/MS/MS | 0.15-15 µg/mL | Human EDTA Plasma |
| Acetaminophen | Pain | LC/MS/MS | 100-10000 ng/mL | Human EDTA Plasma |
| Acetyl salicylic acid; salicylic acid | Pain | LC/MS/MS | 5-1500 ng/mL; 75-7500 ng/mL | Human EDTA Plasma |
| Acetylsalicylic Acid | Pain | LC/MS/MS | 2-300 ng/mL | Buffered Human EDTA Plasma |
| Acyclovir | Infectious Disease | LC/MS/MS | 0.5-40 ng/ml | Human Urine |
| Acyclovir | Infectious Disease | LC/MS/MS | 0.5-40000 pg/mL | Human EDTA Plasma |
| Adefovir | Infectious Disease | LC/MS/MS | 0.1-50 ng/mL | Human EDTA Plasma |
| Alendronic Acid | Endocrinology, Rheumatology | HPLC/FLR | 5-1500 ng/mL | Human Urine |
| Alendronic Acid | Endocrinology, Rheumatology | HPLC/FLR | 5-500 ng/mL | Monkey Urine |
| Alendronic Acid | Endocrinology, Rheumatology | LC/MS/MS | 50-50000 pg/mL | Human Plasma |
| Alfuzosin | Genitourinary | HPLC/FLR | 0.2-100 ng/mL | Human EDTA Plasma |
| Aliskiren | Cardiovascular | LC/MS/MS | 1-500 ng/mL | Human EDTA Plasma |
| Allopurinol; Oxypurinol | Antigout Drugs | LC/MS | 50-2000 ng/mL ;100-10000 ng/mL | Human EDTA Plasma |
| Allopurinol; Oxypurinol | Antigout Drugs | LC/MS/MS | 40-10000 ng/mL; 1-200 µg/mL | Human Urine |
| Alprazolam | Central Nervous System Agents | LC/MS/MS | 0.25-50 ng/mL | Human EDTA Plasma |
| Alvimopan;ADL 08-0011 | Gastrointesninal | LC/MS/MS | 100-20000 pg/mL; 0.5-100 ng/mL | Human EDTA Plasma |
| Amiodarone; Desethylamiodarone | Cardiovascular | LC/MS/MS | 10-25000 ng/mL; 0.5-200 ng/mL | Human EDTA Plasma |
| Amiodarone;Desethylamiodarone | Cardiovascular | LC/MS/MS | 100-4000 ng/mL | Human Sodium Heparinized Plasma |
| Amisulpride | Central Nervous System Agents | LC/MS/MS | 1-500 ng/mL | Human Plasma |
| Amlodipine | Cardiovascular | LC/MS/MS | 20-10000 pg/mL | Human Lithium Heparinized Plasma |
| Amlodipine | Cardiovascular | LC/MS/MS | 50-10000 pg/mL | Human EDTA Plasma |
| Amoxicillin | Infectious Disease | LC/MS/MS | 40-20000 ng/mL | Human EDTA Plasma |
| Amoxicillin | Infectious Disease | LC/MS/MS | 40-12000 ng/mL | Human EDTA K3 Plasma |
| Amphetamine (chiral method) | Central Nervous System Agents | LC/MS/MS | 0.2-100 ng/mL | Human EDTA Plasma |
| Anagrelide | Cardiovascular | LC/MS/MS | 20-5000 pg/mL | Human EDTA Plasma |
| Anastrozole | Oncology | LC/MS/MS | 100-20000 pg/mL | Human EDTA Plasma |
| Androstenedione | Endocrinology | GC/MS/MS | 25-2500 pg/mL | Human Serum |
| Androstenedione | Endocrinology | GC/MS/MS | 25-2500 pg/mL | Human Heparin Plasma |
| Apomorphine | Central Nervous System Agents | LC/MS/MS | 0.25-50 ng/mL | Human Plasma |
| Aprepitant | Gastrointestinal | LC/MS/MS | 20-2000 ng/mL | Human Plasma |
| Aripiprazole | Central Nervous System Agents | LC/MS/MS | 0.50-100 ng/mL | Human EDTA Plasma |
| Armodafinil | Central Nervous System Agents | LC/MS/MS | 20-10000 ng/mL | Human EDTA Plasma |
| Atazanavir | Infectious Disease | LC/MS/MS | 2-2000 ng/mL | Human Plasma |
| Atenolol | Cardiovascular | LC/MS | 5-1000 ng/mL | Human Sodium Heparinized Plasma |
| Atomoxetine | Central Nervous System Agents | LC/MS/MS | 2-500 ng/mL | Human Plasma |
| Atorvastatin lactones | Cardiovascular | LC/MS/MS | 10-10000 pg/mL, 10-5000 pg/mL, 50-50000 pg/mL | Human Plasma |
| Atorvastatin; o-Hydroxy-Atorvastatin; p-Hydroxy-Atorvastatin | Cardiovascular | LC/MS/MS | 0.25-100 ng/mL ; 0.25-20 ng/mL ; 0.25-100 ng/mL | Human Sodium Heparin Plasma |
| Atorvastatin; o-Hydroxy-Atorvastatin; p-Hydroxy-Atorvastatin | Cardiovascular | LC/MS/MS | 50-50000 pg/mL; 50-50000 pg/mL; 50-5000 pg/mL | Human EDTA Plasma |
| Atovaquone | Infectious Disease | LC/MS/MS | 50-25000 ng/mL | Human EDTA Plasma |
| Azithromycin | Infectious Disease | LC/MS/MS | 10-1000 ng/mL | Human EDTA K3 Plasma |
| Azithromycin | Infectious Disease | LC/MS/MS | 50-500 ng/mL | Human EDTA K3 Plasma |